Dana Farber Cancer Institute

Site:	Dana Farber Cancer Institute	Go to their website
Address:	450 Brookline Ave
City:	Boston
State:	MA
Zip:	02215-5450
Country:	USA

70 trials at this site

Phase	Trial [desc]	Trial Status	Site Status	Drug	NCT#
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
2	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Active, not recruiting	Closed	CB-839	NCT03872427
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Active	Rogaratinib	NCT04595747
2	Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor	Active, not recruiting	Not yet activated	Temozolomide	NCT03556384
2	SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas	Completed	Closed	SU5416	NCT00005862
1	Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors	Completed	Closed	AT13387	NCT00878423
1	Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors	Ongoing, but not recruiting	Closed	XL147	NCT00486135
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862
1	Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	STA-9090	NCT00688116
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Active, not recruiting	Active, not recruiting	LOXO-101	NCT02576431
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
3	Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients	Terminated	Closed	Imatinib	NCT01031628
1	Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)	Completed	Closed	Imatinib and Nilotinib	NCT00135005
2	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT06208748
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
1	Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)	Completed	Closed	IPI-504	NCT00276302
1	Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Active, not recruiting	Closed	Nivolumab + BMS-986016	NCT01968109
3	Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy	No longer avalable	Closed	Regorafenib (BAY 73-4506)	NCT01646593

Dana Farber Cancer Institute

70 trials at this site

Page 1 of 4 | Next | Last